title: [Effect of pentoxifylline on survival, cardiac function and both portal and systemic hemodynamics in advanced alcoholic cirrhosis--a randomized double-blind placebo-controlled trial].
abstract: OBJECTIVE
  To assess the effect of pentoxiphylline (a potent inhibitor of tumor necrosis factor alpha) on survival, on systemic and portal hemodynamics, and on cardiac function in patients with alcoholic cirrhosis.
  
  
  METHODS
  A randomized double-blind placebo-controlled trial.
  
  
  METHODS
  A single center using parallel groups of patients to compare pentoxiphylline with placebo.
  
  
  METHODS
  We recruited 24 patients with alcoholic cirrhosis (8 Child-Pugh B and 16 Child-Pugh C).
  
  
  METHODS
  Patients were randomly assigned to receive pentoxiphylline (400 mg tid; n = 12) or placebo (n = 12) over a 4-week period.
  
  
  METHODS
  The primary outcome was to extend short-term and long-term survival. Secondary outcomes included hemodynamic benefits (improvement in cardiac function and/or systemic vascular resistance index, or decrease in portal pressure).
  
  
  RESULTS
  Portal pressure and cardiac function remained unchanged and there were no significant differences in short-term or long-term survival between treatment and placebo groups. The group on pentoxiphylline increased systemic vascular resistance and decreased cardiac indices (from 1,721 +/- 567 to 2,082 +/- 622 dyn.sec(-1) cm(-5) m(-2) and from 4.17 +/- 1.4 to 3.4 +/- 0.9 l.m(-2), p = 0.05).
  
  
  CONCLUSIONS
  Although pentoxiphylline seems to provide some short-term hemodynamic benefits in patients with advanced alcoholic cirrhosis, this drug has no effect on survival or portal pressure in these patients.
authors.affiliation: Unidad de Gastroenterología y Hepatología, Hospital Universitario Fundación Alcorcón, Avda, Budapest, 1. 28922 Alcorcón, Madrid. cfernandez@fhalcorcon.es
authors.forename: C M
authors.initials: CM
authors.lastname: Fernández-Rodríguez
authors.forename: J L
authors.initials: JL
authors.lastname: Lledó
authors.forename: P
authors.initials: P
authors.lastname: López-Serrano
authors.forename: M L
authors.initials: ML
authors.lastname: Gutiérrez
authors.forename: S
authors.initials: S
authors.lastname: Alonso
authors.forename: M T
authors.initials: MT
authors.lastname: Pérez-Fernández
authors.forename: M
authors.initials: M
authors.lastname: Fernández Gil
authors.forename: R
authors.initials: R
authors.lastname: Pazos
authors.forename: R
authors.initials: R
authors.lastname: Tolon
authors.forename: T
authors.initials: T
authors.lastname: Hernández
authors.forename: P
authors.initials: P
authors.lastname: Sanz
mesh_terms: D004311:Double-Blind Method; D005260:Female; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008104:Liver Cirrhosis, Alcoholic / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000627:therapeutic use*; D011168:Portal System / Q000187:drug effects / Q000503:physiopathology; D012720:Severity of Illness Index; D015996:Survival Rate; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D014409:Tumor Necrosis Factor-alpha; D010431:Pentoxifylline